ProCE Banner Activity

Hereditary Angioedema: Accounting for Unpredictability When Developing a Management Plan

Clinical Thought

In this commentary, Marc Riedl, MD, MS, discusses the important elements to consider when devising an effective management plan for patients with hereditary angioedema (HAE).

Released: October 31, 2022

Expiration: October 30, 2023

Share

Supporters

This activity is supported by educational grants from

BioCryst Pharmaceuticals, Inc.

Takeda Pharmaceuticals U.S.A., Inc.

Partners

NAPNAP

ProCE Banner

Faculty Disclosure

Marc Riedl, MD, MS: researcher: Biocryst, CSL Behring, Ionis, Klavista, Pharvaris, Takeda; consultant/advisor/speaker: Astria, Biocryst, Biomarin, CSL Behring, Cycle Pharma, Ipsen, Klavista, Ono Pharma, Pfizer, Pharming, Pharvaris, RegenexBio, Spark, Takeda.

Additional Information

Program Medium

This program has been made available online.